Verbal repetition in patients with Alzheimer's disease who receive donepezil

International Journal of Geriatric Psychiatry

Volumn 21, Issue 5, 2006, Pages 426-431

  Asp, Elissa ^a,b   Cloutier, France ^a   Fay, Sherri ^a   Cook, Cheryl ^a   Robertson, Mary Lou ^a   Fisk, John ^a   Dei, Ding Wai ^a   Rockwood, Kenneth ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b SAINT MARY S UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Donepezil; Frontal lobe function; Goal Attainment Scaling; Repetition

Indexed keywords

DONEPEZIL;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; BRAIN FUNCTION; CANADA; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; COGNITION; COMMUNITY LIVING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GOAL ATTAINMENT; HUMAN; INDIVIDUALIZATION; LEISURE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; OPEN STUDY; PERSEVERATION; RATING SCALE; SCORING SYSTEM; SOCIAL INTERACTION; VERBAL COMMUNICATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDANS; MALE; MEMORY, SHORT-TERM; NOOTROPIC AGENTS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; VERBAL BEHAVIOR;

EID: 33646817072     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.1486     Document Type: Article

References (42)

1. AD2000 Collaborative Group. 2004. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet 363(9427): 2105-2115.
2. Alexander MP, Stuss DT, Fansabedian. 2003. California Verbal Learning Test: performance by patients with focal frontal and non-frontal lesions. Brain 126(6) 1493-1503.
3. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. 1988. Cornell Scale for Depression in Dementia. Biol Psychiatry 23(3): 271-284.
4. Asp E, Song X, Rockwood K. 2005. Self-referential tags in the discourse of people with Alzheimer's disease. Brain Lang 4 September (Epub ahead of print)
5. Baudic S, Barba GD, Thibaudet MC, Smaggeh R, Remy P, Trykov L. 2005. Executive function deficits in early Alzheimer's disease and their relations with episodic memory. Arch Clin Neuropsychol 23 August (Epub ahead of print)
6. Bayles KA, Tomoeda CK, McKnight PE, Helm-Estabrooks N, Hawley JN. 2004. Verbal perseveration in individuals with Alzheimer's Disease. Seminars in Speech Lang 25(4): 335-347.
7. Bayles KA, Tomoeda CK, Kaszniak AW, Stern LZ, Eagans KK. 1985. Verbal perseveration of dementia patients. Brain Lang 25: 102-116.
8. Bourgeois MS, Burgio LD, Schulz R, Beach S, Palmer B. 1997. Modifying repetitive verbalizations of community-dwelling patients with AD. Gerontologist 37(1): 30-39.
9. Borgo F, Giovannini L, Moro R, Semenza C, Arcicasa M, Zaramella M. 2003. Updating and inhibition processes in working memory: a comparison between Alzhiemer's type dementia and frontal lobe focal damage. Brain cog 53: 197-201.
10. Cabeza R, Nyberg L. 2000. Imaging cognition II: an empirical review of review of 275 PET and fMRI studies. J Cog Neurosci 12: 1-47.
11. Casasanto DJ, Killgore WDS, Maldjian JA, et al. 2002. Neural correlates of successful and unsuccessful verbal memory encoding. Brain Lang 80: 287-295.
12. Cohen-Mansfield J. 1986. Agitated behaviors in the elderly II. Preliminary results in the cognitively deteriorated. J Am Geriatr Soc 34(11): 722-727.
13. Davis LL, Buckwalter K, Burgio LD. 1997. Measuring problem behaviors in dementia: Developing a methodological agenda. Advan in Nursing Sci 20(1): 40-55.
14. Folstein MF, Folstein S, McHugh PR. 1975. 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
15. Gallo DA, Sullivan AL, Daffner KR, Schacter DL, Budson AE. 2004. Associative Recognition in Alzheimer's disease: evidence for impaired recall-to-reject. Neuropsychol 18(3): 556-563.
16. Gellin Shindler A, Caplan LR, Hier DB. 1984. Intrusions and Perseverations. Brain Lang 23: 148-158.
17. Gordon JE, Powell C, Rockwood, K. 1999. Goal attainment scaling as a measure of clinically important change in nursing-home patients. Age Ageing 28: 275-281.
18. Grady CL, McIntosh AR, Beig S, et al. 2003. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's Disease. J Neurosci 23(3): 986.
19. Hanyu H, Shimizu T, Tanaka Y, Takasaki M, Koizumi K, Abe K. 2003. Regional Cerebral Blood Flow Patterns and Response to Donepezil Treatment in Patients with Alzheimer's Disease. Dementia Geriatr Cog Disord 15(4): 177-182.
20. Kaasinen V, Nagren K, Jarvenpaa T, et al. 2002. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmaco 22(6): 615-620.
21. Lambon Ralph MA, Patterson K, Graham N, Dawson K, Hodges JR. 2003. Homogeneity and heterogeneity in mild cognitive impairment and Alzheimer's disease: a cross-sectional and longitudinal study of 55 cases. Brain 126(11): 2350-2362.
22. Lojkowska W, Ryglewicz D, Jedrzejczak T, et al. 2003. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J Neurologic Sci 216(15): 119-126.
23. Mattis S. 1976. Dementia Rating Scale. In Geriatric Psychiatry 1, Bellack R, Karasuv B (eds). Grune & Stratton: New York: 77-121.
24. Mega MS, Dinov ID, Lee L, et al. 2000. Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 12(2): 209-218.
25. Mitnitski AB, Mogilner AJ, Graham JE, Rockwood K. 2003. Techniques for knowledge discovery in existing biomedical databases: estimation of individual aging effects in cognition in relation to dementia. J Clin Epidemiol 56: 116-123.
26. Moscovitch M. 1982. Multiple dissociations of function in Amnesia. In Human Memory and Amnesia Cermak L (ed.). Earlbaum, Hillsdale, NJ; 337-370.
27. Nobili F, Koulibaly M, Vitali P, et al. 2002. Brain perfusion follow-up in alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nuclear Med 43(8): 983-990.
28. Potkin SG, Anand R, Fleming K, et al. 2001. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol 4: 223-230.
29. Rockwood K, Black SE, Robilliard A, Lussier I. 2004. Potential treatment effects of donepezil not detected in Alzheimer's disease clinical trials: a physician survey. Int J Geriatr Psychiatry 19: 954-960.
30. Rockwood K. 2004. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 75: 677-685.
31. Rockwood K, Mogilner A, Mitnitski A. 2004. Changes with age in the distribution of a frailty index. Mechan Ageing Develop 125(7): 517-519.
32. Rockwood K, Graham JE, Fay S. 2002. Goal setting and attainment in Alzheimer's disease patients treated with donepezil. J Neurol Neurosurg Psychiatry 73(5): 500-507.
33. Rockwood K, MacKnight C. 2001. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemiol 20: 51-56.
34. Rockwood K, Stolee P, Fox RA. 1993. Use of goal attainment scaling in measuring clinically important change in the frail elderly. J Clin Epidemiol 46(10): 1113-1118.
35. Rockwood K, Wallack M, Tallis R. 2003. The treatment of Alzheimer's disease: success short of cure. Lancet Neurol 2: 630-633.
36. Rosen WG, Mohs RC, Davis KL. 1984. A new rating scale for Alzheimer's disease. Am J Psychiatry 141(11): 1356-1364.
37. Saykin A, Flashman L, Johnson S, et al. 2000. Frontal and hippocampal memory circuitry in early Alzheimer's disease: relation of functional MRI changes. NeuroImage 11(5): S123.
38. Saykin AJ, Wishart HA, Rabin LA, et al. 2004. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 127(7): 1574-1583.
39. Shimamura AP, Janowsky JS, Squire LR. 1991. What is the role of frontal lobe damage in memory disorders? In Frontal Lobe Function and Dysfunction, Levin HS, Eisenberg HM, Benton AL (eds). Oxford University Press: New York; 173-195.
40. Tune L, Tiseo PJ, Ieni J, et al. 2003. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 11: 169-177.
41. Veltman DJ, Rombouts SARB, Dolan RJ. 2003. Maintenance versus manipulation in verbal working memory revisited: an fMRI study. NeuroImage 18(2): 247-256.
42. Wenk GL. 2003. Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry 64(Suppl. 9): 7-10.